512 related articles for article (PubMed ID: 17078381)
41. Variable expression of WASP in B cell lines of Wiskott-Aldrich syndrome patients.
Remold-O'Donnell E; Cooley J; Shcherbina A; Hagemann TL; Kwan SP; Kenney DM; Rosen FS
J Immunol; 1997 May; 158(9):4021-5. PubMed ID: 9126958
[TBL] [Abstract][Full Text] [Related]
42. The usefulness of X-linked polymorphic loci as gene markers to track X allele and chimerism in a post-allogeneic peripheral blood stem cell transplant patient with Wiskott-Aldrich syndrome.
Sasanakul W; Hongeng S; Chuansumrit A; Chaiyaratana W; Pakakasama S; Hathirat P
J Med Assoc Thai; 2001 Mar; 84(3):379-84. PubMed ID: 11460939
[TBL] [Abstract][Full Text] [Related]
43. Hematopoietic stem cell transplantation from a donor with Klinefelter syndrome for Wiskott-Aldrich syndrome.
Balci YI; Turul T; Daar G; Anak S; Devecioglu O; Tezcan I; Cetinkaya DU
Pediatr Transplant; 2008 Aug; 12(5):597-9. PubMed ID: 18331539
[TBL] [Abstract][Full Text] [Related]
44. Wiskott-Aldrich syndrome protein and the cytoskeletal dynamics of dendritic cells.
Calle Y; Chou HC; Thrasher AJ; Jones GE
J Pathol; 2004 Nov; 204(4):460-9. PubMed ID: 15495215
[TBL] [Abstract][Full Text] [Related]
45. WIP null mice display a progressive immunological disorder that resembles Wiskott-Aldrich syndrome.
Curcio C; Pannellini T; Lanzardo S; Forni G; Musiani P; Antón IM
J Pathol; 2007 Jan; 211(1):67-75. PubMed ID: 17086554
[TBL] [Abstract][Full Text] [Related]
46. Identification of six novel WASP gene mutations in patients suffering from Wiskott-Aldrich syndrome.
Brooimans RA; van den Berg AJ; Tamminga RY; Revesz T; Wulffraat NM; Zegers BJ
Hum Mutat; 2000 Apr; 15(4):386-7. PubMed ID: 10737997
[TBL] [Abstract][Full Text] [Related]
47. Identification of WASP mutations in 10 Australian families with Wiskott-Aldrich syndrome and X-linked thrombocytopenia.
Bourne HC; Weston S; Prasad M; Edkins E; Benson EM
Pathology; 2004 Jun; 36(3):262-4. PubMed ID: 15203732
[TBL] [Abstract][Full Text] [Related]
48. A case of Wiskott-Aldrich syndrome with de novo mutation at exon 4.
Doğu F; Ariga T; Ikincioğullari A; Bozdoğan G; Aytekin C; Metin A; Babacan E
Turk J Pediatr; 2006; 48(1):66-8. PubMed ID: 16562789
[TBL] [Abstract][Full Text] [Related]
49. WASP (Wiskott-Aldrich syndrome protein) gene mutations and phenotype.
Imai K; Nonoyama S; Ochs HD
Curr Opin Allergy Clin Immunol; 2003 Dec; 3(6):427-36. PubMed ID: 14612666
[TBL] [Abstract][Full Text] [Related]
50. FLI1 Induces Megakaryopoiesis Gene Expression Through WAS/WIP-Dependent and Independent Mechanisms; Implications for Wiskott-Aldrich Syndrome.
Wang C; Sample KM; Gajendran B; Kapranov P; Liu W; Hu A; Zacksenhaus E; Li Y; Hao X; Ben-David Y
Front Immunol; 2021; 12():607836. PubMed ID: 33717090
[TBL] [Abstract][Full Text] [Related]
51. Hematopoietic stem cell transplantation for X-linked thrombocytopenia from a mild symptomatic carrier.
Okuya M; Kurosawa H; Kubota T; Endoh K; Ogiwara A; Nonoyama S; Hagisawa S; Sato Y; Matsushita T; Fukushima K; Sugita K; Sato T; Arisaka O
Bone Marrow Transplant; 2010 Mar; 45(3):607-9. PubMed ID: 19684625
[No Abstract] [Full Text] [Related]
52. The Wiskott-Aldrich syndrome: The actin cytoskeleton and immune cell function.
Blundell MP; Worth A; Bouma G; Thrasher AJ
Dis Markers; 2010; 29(3-4):157-75. PubMed ID: 21178275
[TBL] [Abstract][Full Text] [Related]
53. Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott - Aldrich Syndrome.
Rai R; Romito M; Rivers E; Turchiano G; Blattner G; Vetharoy W; Ladon D; Andrieux G; Zhang F; Zinicola M; Leon-Rico D; Santilli G; Thrasher AJ; Cavazza A
Nat Commun; 2020 Aug; 11(1):4034. PubMed ID: 32788576
[TBL] [Abstract][Full Text] [Related]
54. Characterization of Wiskott-Aldrich syndrome (WAS) mutants using Saccharomyces cerevisiae.
Rajmohan R; Raodah A; Wong MH; Thanabalu T
FEMS Yeast Res; 2009 Dec; 9(8):1226-35. PubMed ID: 19817875
[TBL] [Abstract][Full Text] [Related]
55. Wiskott-Aldrich syndrome protein-deficient hematopoietic cells can be efficiently mobilized by granulocyte colony-stimulating factor.
Charrier S; Blundell M; Cédrone G; Louache F; Vainchenker W; Thrasher AJ; Galy A
Haematologica; 2013 Aug; 98(8):1300-8. PubMed ID: 23445877
[TBL] [Abstract][Full Text] [Related]
56. Genome editing for primary immunodeficiencies: A therapeutic perspective on Wiskott-Aldrich syndrome.
Naseem A; Steinberg Z; Cavazza A
Front Immunol; 2022; 13():966084. PubMed ID: 36059471
[TBL] [Abstract][Full Text] [Related]
57. Current understanding of the Wiskott-Aldrich syndrome and prospects for gene therapy.
Trifari S; Marangoni F; Scaramuzza S; Aiuti A; Roncarolo MG; Dupré L
Expert Rev Clin Immunol; 2007 Mar; 3(2):205-15. PubMed ID: 20477109
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of gene therapy for Wiskott-Aldrich syndrome using a WAS promoter/cDNA-containing lentiviral vector and nonlethal irradiation.
Dupré L; Marangoni F; Scaramuzza S; Trifari S; Hernández RJ; Aiuti A; Naldini L; Roncarolo MG
Hum Gene Ther; 2006 Mar; 17(3):303-13. PubMed ID: 16544979
[TBL] [Abstract][Full Text] [Related]
59. [Molecular pathogenesis of Wiskott-Aldrich syndrome].
Sasahara Y; Tsuchiya S
Nihon Rinsho Meneki Gakkai Kaishi; 2005 Jun; 28(3):140-7. PubMed ID: 15997177
[TBL] [Abstract][Full Text] [Related]
60. Lessons from the Wiskott-Aldrich syndrome.
Puck JM; Candotti F
N Engl J Med; 2006 Oct; 355(17):1759-61. PubMed ID: 17065636
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
